Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

Trial Profile

Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Guselkumab (Primary) ; Adalimumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms VOYAGE 1
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 22 Sep 2017 Results (n=1829) of pooled analysis of VOYAGE 1 and VOYAGE 2 studies assessing efficacy published in the British Journal of Dermatology.
    • 16 Sep 2017 Results from an open label extension period of this trial published in the Janssen Research and Development Media Release
    • 16 Sep 2017 According to a Janssen media release, results from an open label extension period of the study have been presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top